cbdMD, Inc.
YCBDcbdMD, Inc. in brief
cbdMD, Inc. is a listed company in the Pharmaceutical industry, based in Charlotte, North Carolina, USA. Its market value was $4 M on 30 October 2026, which makes it the 27,060th largest listed company in the world and the 4,424th largest in the USA on this site. In the year to September 2025 it had sales of $19 M and a net loss of $2 M. It employs about 42 people and Ronan Kennedy is its chief executive. Its shares trade under the symbol YCBD (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
cbdMD, Inc. timeline
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- ✎Renamed Level Brands, Inc.Formerly Level Beauty Group, Inc..
- 2017
- 🔔· approximateInitial public offering on NYSE
- 2019
- ✎Renamed cbdMD, Inc.Formerly Level Brands, Inc..
- 2021
- 💰Record revenue of $44 millionFY2021, the highest of the 8 years on record.
Events of cbdMD, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,933 (Jan 2020) · #3,419 (Jan 2021) · #4,776 (Jan 2022) · #5,407 (Dec 2022) · #5,654 (Jul 2023) · #4,685 (Jan 2024) · #2,400 (Mar 2026) · #4,124 (Aug 2026) · #4,359 (Sep 2026) · #4,424 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.2×
- Price / book
- 0.6×
- Free cash flow yield
- -37.3%
- Net margin (TTM)
- -13.8%
- Operating margin
- -11.3%
- Return on equity
- -40.0%
- Liabilities / assets
- 30.6%
- Net debt
- $-2M
- Revenue growth
- -1.5%
- Revenue per employee
- $457 K
- Profit per employee
- $-49 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $19M | -1.5% | $-2M | $-2M | -10.6% |
| Sep 2024 | $19M | -19.4% | $-3M | $-4M | -19.0% |
| Sep 2023 | $24M | -31.8% | $-22M | $-23M | -95.0% |
| Sep 2022 | $35M | -20.4% | $-78M | $-70M | -198.0% |
| Sep 2021 | $44M | +6.2% | $-20M | $-23M | -52.6% |
| Sep 2020 | $42M | +77.1% | $-18M | $13M | 30.1% |
| Sep 2019 | $24M | +5041.3% | $-15M | $-51M | -217.2% |
| Sep 2018 | $0M | — | $-2M | $0M | 13.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-1M | $0M | $-2M | $-1.09 | — |
| Sep 2024 | $-0M | $0M | $-1M | $-14.29 | — |
| Sep 2023 | $-4M | $0M | $-5M | $-13.32 | — |
| Sep 2022 | $-15M | $1M | $-16M | $-55.80 | — |
| Sep 2021 | $-14M | $0M | $-14M | $-0.47 | — |
| Sep 2020 | $-11M | $1M | $-12M | $0.28 | — |
| Sep 2019 | $-15M | $1M | $-17M | $0.00 | — |
| Sep 2018 | $-6M | $0M | $-6M | $0.00 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $6M (+20.4% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 4, 20268-KCurrent reportAcquisition or disposal completed · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events
- Sep 2, 20268-KCurrent reportMaterial agreement · Bylaws amended · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- May 20, 20268-KCurrent reportMaterial agreement · New financial obligation
- May 14, 202610-QQuarterly report · period to Mar 2026
- Apr 15, 20268-KCurrent reportOther events
- Apr 1, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Mar 4, 2026424B4IPO prospectus
- Feb 20, 2026S-1/AIPO registration (amended)
- Feb 17, 202610-QQuarterly report · period to Dec 2025
- Feb 12, 2026DEF 14AProxy statement
- Jan 22, 2026S-1IPO registration
Official filings of cbdMD, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $19 M
- Operating income
- $-2 M
- Net income
- $-2 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $3 M
- Total equity
- $7 M
As of September-2025
Top 27 institutional investors in cbdMD, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | CSS Llc/il | 137,621 | 0 (0.00%) | 1.23% | $0 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 119,645 | 0 (0.00%) | 1.07% | $0 M | Nov 13, 2026 |
| 3 | HRT Financial LP | 97,538 | New | 0.87% | $0 M | Nov 13, 2026 |
| 4 | Citadel Advisors LLC | 92,971 | New | 0.83% | $0 M | Nov 16, 2026 |
| 5 | Chapin Davis, Inc. | 81,250 | 0 (0.00%) | 0.73% | $0 M | Oct 9, 2026 |
| 6 | Alesco Advisors, LLC, An ESL Co | 68,513 | 0 (0.00%) | 0.61% | $0 M | Nov 16, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 47,157 | 0 (0.00%) | 0.42% | $0 M | Nov 13, 2026 |
| 8 | Jane Street Group, LLC | 45,023 | -9,378 (-17.24%) | 0.40% | $0 M | Nov 12, 2026 |
| 9 | Chicago Partners Investment Group LLC | 37,275 | -40,823 (-52.27%) | 0.33% | $0 M | Oct 27, 2026 |
| 10 | Virtu Financial LLC | 35,941 | +25,450 (+242.59%) | 0.32% | $0 M | Nov 17, 2026 |
| 11 | Susquehanna International Group, LLP | 19,783 | New | 0.18% | $0 M | Nov 16, 2026 |
| 12 | UBS Group AG | 18,344 | -3,232 (-14.98%) | 0.16% | $0 M | Nov 10, 2026 |
| 13 | StoneX Group Inc. | 16,335 | +3,603 (+28.30%) | 0.15% | $0 M | Nov 3, 2026 |
| 14 | Commonwealth Equity Services, LLC | 16,255 | 0 (0.00%) | 0.15% | $0 M | Nov 2, 2026 |
| 15 | Northern Trust Corp | 10,307 | -4,596 (-30.84%) | 0.09% | $0 M | Nov 16, 2026 |
| 16 | Beacon Pointe Advisors, LLC | 10,000 | New | 0.09% | $0 M | Nov 16, 2026 |
| 17 | Harbour Investments, Inc. | 5,200 | 0 (0.00%) | 0.05% | $0 M | Nov 9, 2026 |
| 18 | Morgan Stanley | 1,139 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 19 | BlackRock, Inc. | 1,080 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 20 | Osaic Holdings, Inc. | 49 | -14 (-22.22%) | 0.00% | $0 M | Nov 12, 2026 |
| 21 | HHM Wealth Advisors, LLC | 8 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 22 | Pinnacle Financial Group, Inc. | 8 | — | 0.00% | $0 M | Nov 16, 2026 |
| 23 | Farther Finance Advisors, LLC | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 24 | Group One Trading LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 25 | Golden State Wealth Management, LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
Show all 27: investors 26 to 27
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Rothschild Investment LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 27 | Rockefeller Capital Management L.P. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding cbdMD, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 119,645 | $0 M | 1.1% | <0.01% | +134% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 1,123 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at cbdMD, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | William F. Raines IIIDirector | Grant or award | +1,572 | — | — | 13,676 | Form 4 |
| filed | Jeffrey H. PorterDirector | Grant or award | +1,572 | — | — | 3,144 | Form 4 |
| filed | Sibyl Nichole SwiftDirector | Grant or award | +1,572 | — | — | 4,145 | Form 4 |
| filed | Bakari T. SellersDirector | Grant or award | +1,572 | — | — | 4,324 | Form 4 |
| filed | Kevin Charles RoeDirector | Grant or award | +1,572 | — | — | 26,707 | Form 4 |
| filed | Scott G. StephenDirector | Grant or award | +1,572 | — | — | 4,412 | Form 4 |
| filed | Clark R. Crosnoe10% owner | Sellindirect | -461,725 | $2.310 | $1.1 M | 361,400 | Form 4 |
| filed | Clark R. Crosnoe10% owner | Sellindirect | -69,875 | $2.340 | $164 K | 56,875 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: cbdMD, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-12-19 19:05 UTC, code T3, resumed 20:20 UTC
- 2025-12-18 18:53 UTC, code M, resumed 18:58 UTC
- 2025-12-12 14:52 UTC, code M, resumed 14:57 UTC
- 2025-09-29 15:26 UTC, code M, resumed 15:31 UTC
- 2025-09-29 14:49 UTC, code M, resumed 14:54 UTC
Fails to deliver
- : 7,524 shares at $0.39
- : 339 shares at $0.36
- : 406 shares at $0.37
- : 7,805 shares at $0.39
- : 68,968 shares at $0.44
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
cbdMD, Inc. scorecard#
Passes 4 of the 19 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Pharmaceutical's median of 3.5×.
- ✗Free cash flow yield above 5%-37.3%Free cash flow is -37.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 6
- ✗Revenue grew in the newest year-1.5%Revenue down 1.5% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-18.5%-18.5% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-18.5%-18.5% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-1.09 vs -14.29Diluted EPS -1.09 in fiscal 2025 against -14.29 the year before (report's currency).
- ✗Net income higher than five years earlier-$2 M-$2 M in fiscal 2025 against $13 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-11.3%-11.3% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-44.4%-44.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-11.3%-11.3% in fiscal 2025 against -221.1% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.05 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-21.74Z-score -21.74 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from cbdMD, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -11.3% | 1.8% | |
| Net margin | -10.6% | -1.5% | |
| Return on equity | -44.4% | -0.9% | |
| Revenue growth, 3 years a year | -18.5% | 2.5% | |
| Revenue growth | -1.5% | 7.3% | |
| Free cash flow margin | -8.5% | 6.0% |
5of 8on the Piotroski tests of financial strength
- Revenue fell 1.5% against the year before.
- Net loss of $2 million, the 5th loss-making year in a row.
- Free cash flow was negative: -$2 million.
- Receivables grew 27% while revenue grew -1%: customers are paying later, or sales were booked ahead of cash.
cbdMD, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 19−1.5%100% | 19−19.3%100% | 24−31.8%100% | 35−20.4%100% | 44+6.2%100% | 42+77.1%100% | 24+5052%100% | 0.5r8.4−89.7%100% | 4.5+120%100% | 2.0—100% | |
| Cost of revenue | 7.2−3.5%37.6% | 7.5−18.4%38.4% | 9.2−29.8%38.0% | 13−9.9%36.9% | 14−6.6%32.6% | 16+69.8%37.0% | 9.1+8684%38.6% | 0.1r2.7−92.3%22.7% | 1.4−16.3%30.3% | 1.6—79.7% | |
| Gross profit | 12−0.2%62.4% | 12−19.9%61.6% | 15−32.9%62.0% | 22−25.5%63.1% | 30+13.7%67.4% | 26r26+81.7%63.0% | 15+3988%61.4% | 0.4r5.7−88.6%77.3% | 3.1+655%69.7% | 0.4—20.3% | |
| Operating expenses | — | — | — | — | 50+12.9%112% | 44+49.9%105% | 29+1262%124% | 2.2r5.6−35.9%469% | 3.4−19.0%75.1% | 4.1—204% | |
| Operating income | −2.2—−11.3% | −3.3—−17.0% | −22—−93.1% | −78—−221% | −20—−44.1% | −18r−18—−42.0% | −15—−62.6% | −1.8r0.0—−391% | −1.4—−30.4% | −3.9—−191% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | 0.0−99.8%0.2% | 0.5+223%11.2% | 0.2—7.6% | |
| Net interest income | 0.0—0.2% | −0.0−146%−0.2% | 0.1+292%0.3% | 0.0—0.0% | −0.0−173%−0.1% | 0.0−46.9%0.1% | 0.1—0.3% | 0—0.0% | — | — | |
| Other non-operating income (expense) | — | — | 0−100%0.0% | 0.2+712%0.7% | 0.0—0.1% | — | — | — | — | — | |
| Income before tax | −2.0—−10.6% | −3.7—−19.0% | −23—−95.0% | −70—−198% | −24−315%−54.6% | 11r11—27.0% | −48—−202% | −1.8—−391% | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.9r0.9−167%−2.0% | 1.3r−1.3—3.2% | −2.4—−10.0% | 0r0.0−100%0.0% | 0.0+213%0.6% | 0.0—0.4% | |
| Income from continuing operations | — | — | — | — | — | 13—30.2% | −45—−192% | −1.8r0.1—−391% | −0.2—−5.3% | −3.7—−184% | |
| Income from discontinued operations | — | — | — | — | 0—0.0% | −0.0—−0.1% | −5.9−419%−25.1% | 1.9—405% | — | — | |
| Net income including minority interests | — | — | — | — | — | — | — | 0.1—13.7% | −1.4—−31.0% | −3.9—−192% | |
| Net income attributable to shareholders | −2.0—−10.6% | −3.7—−19.0% | −23—−95.0% | −70—−198% | −23−286%−52.6% | 13r13—30.1% | −51−81835%−217% | 0.1—13.7% | −1.4—−31.0% | −3.9—−192% | |
| Earnings per share, basic | -1.09—— | -14.29r-1.79—— | -13.32—— | -55.80r-1.24—— | -0.47−268%— | 0.28—— | -2.82—— | -0.05—— | -0.38—— | -1.13—— | |
| Earnings per share, diluted | -1.09—— | -14.29r-1.79—— | -13.32—— | -55.80r-1.24—— | -0.47−268%— | 0.28—— | 0.00—— | 0.00r-0.05—— | -0.38—— | -1.13—— | |
| Shares, weighted average (basic) | 4.0+646%— | 0.5r4.3−73.3%— | 2.0+52.3%— | 1.3r60−97.6%— | 55+24.5%— | 44+147%— | 18+131%— | 7.7—— | — | — | |
| Shares, weighted average (diluted) | 4.0+646%— | 0.5r4.3−73.3%— | 2.0+52.3%— | 1.3r60−97.6%— | 55+21.6%— | 45+153%— | 18+131%— | 7.7r7.7+71.3%— | 4.5+51.8%— | 3.0—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 2.3−7.8%21.7% | 2.5+36.4%23.2% | 1.8−73.2%11.1% | 6.7−74.6%16.5% | 26+78.2%21.1% | 15+216%13.4% | 4.7+9.5%5.0% | 4.3+1407%28.5% | 0.3+730%4.0% | 0.0—2.1% | |
| Short-term investments | — | — | — | 0−100%0.0% | 0.0+26.0%0.0% | 0.0−86.7%0.0% | 0.2−81.1%0.2% | 1.1—7.0% | 0—0.0% | — | |
| Receivables | 0.8+26.5%7.5% | 0.6−48.9%5.9% | 1.2r0.6+345%7.5% | 0.3—0.7% | — | — | 0−100%0.0% | 0.5—3.1% | 0—0.0% | — | |
| Inventory | 2.9+16.7%28.3% | 2.5−40.4%23.9% | 4.2r4.2−11.2%26.2% | 4.8−14.5%11.7% | 5.6+13.9%4.5% | 4.9−6.0%4.4% | 5.2+4124%5.5% | 0.1−79.1%0.8% | 0.6−4.2%8.3% | 0.6—37.8% | |
| Other current assets | 0.3r0.3−31.9%2.7% | 0.4−45.8%3.8% | 0.8+6.9%4.6% | 0.7−38.8%1.7% | 1.1—0.9% | — | — | — | — | — | |
| Current assets | 6.6+2.5%62.9% | 6.4−20.8%60.4% | 8.1−49.6%49.8% | 16−56.1%39.3% | 37+53.9%29.2% | 24+50.6%21.4% | 16+33.5%16.7% | 12+219%78.5% | 3.7+286%52.2% | 1.0—58.9% | |
| Property, plant and equipment | 0.3−38.9%2.7% | 0.5−36.6%4.3% | 0.7−13.0%4.4% | 0.8−67.9%2.0% | 2.6−19.5%2.1% | 3.2+85.6%2.9% | 1.7+3108%1.8% | 0.1−60.5%0.4% | 0.1−24.9%1.9% | 0.2—11.1% | |
| Right-of-use (leased) assets | 0.7+720%6.8% | 0.1−97.4%0.8% | 3.4−25.2%20.7% | 4.5−20.3%11.0% | 5.6−18.0%4.5% | 6.9—6.2% | 0—0.0% | — | — | — | |
| Goodwill | 0—0.0% | — | 0—0.0% | 0−100%0.0% | 57+3.7%45.4% | 550.0%49.3% | 55—57.8% | 0—0.0% | — | — | |
| Other intangible assets | 2.1−26.5%20.4% | 2.9−10.2%27.3% | 3.2−82.0%19.9% | 18−22.5%43.7% | 23+6.3%18.4% | 220.0%19.5% | 22+582%22.9% | 3.2−2.0%21.1% | 3.2+566%45.8% | 0.5—30.0% | |
| Total assets | 10−1.5%100% | 11−34.7%100% | 16−60.3%100% | 41−67.3%100% | 125+12.7%100% | 111+17.3%100% | 95+529%100% | 15+112%100% | 7.1+335%100% | 1.6—100% | |
| Accounts payable | 1.2−23.8%11.3% | 1.5−19.2%14.6% | 1.9−6.4%11.8% | 2.0−31.6%5.0% | 3.0+4.5%2.4% | 2.9−5.7%2.6% | 3.0+538%3.2% | 0.5+19.1%3.2% | 0.4+92.9%5.6% | 0.2—12.7% | |
| Customer deposits | — | — | — | — | — | — | 0.0—0.0% | 0—0.0% | — | — | |
| Current liabilities | 3.2−62.9%30.7% | 8.6+84.5%81.4% | 4.7−11.6%28.8% | 5.3−23.6%13.0% | 6.9−10.0%5.5% | 7.7+107%6.9% | 3.7+282%3.9% | 1.0−36.3%6.5% | 1.5−20.0%21.6% | 1.9—117% | |
| Long-term debt | — | — | 0.0−100.0%0.0% | 0.1+15.1%0.3% | 0.1−58.8%0.1% | 0.3—0.2% | — | — | — | — | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 2.4−34.7%14.8% | 3.7−24.3%9.0% | 4.9−19.2%3.9% | 6.0—5.4% | 0—0.0% | — | — | — | |
| Non-current liabilities | 0—0.0% | 0−100%0.0% | 2.5−38.9%15.4% | 4.1−72.5%10.0% | 15−38.2%11.9% | 24−54.9%21.6% | 53+186569%56.3% | 0.0−92.8%0.2% | 0.4+3208%5.6% | 0.0—0.7% | |
| Total liabilities | 3.2−62.9%30.7% | 8.6+20.3%81.4% | 7.2−23.5%44.2% | 9.4−56.9%23.0% | 22−31.3%17.4% | 32−44.4%28.6% | 57+5600%60.2% | 1.0−48.0%6.6% | 1.9+0.2%27.2% | 1.9—118% | |
| Retained earnings | −179—−1722% | −182—−1721% | −174—−1077% | −147—−361% | −73—−58.7% | −47—−42.8% | −60—−63.1% | −6.7—−44.4% | −6.3—−88.5% | −4.5—−276% | |
| Shareholders' equity | 7.2+268%69.3% | 2.0−78.3%18.6% | 9.0−71.3%55.8% | 31−69.5%77.0% | 103+30.3%82.6% | 79+111%71.4% | 38+168%39.8% | 14r13+233%93.4% | 4.2+1059%59.6% | 0.4—22.4% | |
| Minority interests | — | — | — | — | — | — | 0−100%0.0% | 1.4+50.7%9.4% | 0.9—13.3% | −0.7—−40.4% | |
| Total equity | — | — | — | — | — | — | 38+168%39.8% | 14+172%93.4% | 5.1—72.8% | −0.3—−18.0% | |
| Total liabilities and equity | 10−1.5%100% | 11−34.7%100% | 16−60.3%100% | 41−67.3%100% | 125+12.7%100% | 111+17.3%100% | 95+529%100% | 15+112%100% | 7.1+335%100% | 1.6—100% | |
| Shares outstanding | 8.9+1711%— | 0.5r3.9−83.4%— | 3.0+120%— | 1.3r61−97.7%— | 58+10.8%— | 52+88.1%— | 28+241%— | 8.1+40.3%— | 5.8+70.3%— | 3.4—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | 1.0+41.2%2.3% | 0.7+149%1.7% | 0.3+30.1%1.2% | 0.2+212%48.5% | 0.1+58.6%1.6% | 0.0—2.2% | |
| Share-based compensation | — | — | — | — | 1.3−31.7%2.9% | 1.9−22.7%4.5% | 2.5+284%10.4% | 0.6+1031%139% | 0.1+394%1.3% | 0.0—0.6% | |
| Cash from operating activities | −1.5—−7.6% | −0.4—−1.8% | −4.3—−17.8% | −15—−42.3% | −14—−31.7% | −11r−11—−25.5% | −15r15—−65.0% | −5.6—−1214% | −2.3—−52.1% | −2.9—−143% | |
| Capital expenditure | −0.2—−1.0% | −0.2—−1.0% | −0.3—−1.2% | −0.7—−1.9% | −0.3—−0.8% | −1.3—−3.2% | −1.2—−5.1% | −0.0—−5.1% | −0.0—−0.2% | −0.1—−6.3% | |
| Intangible assets bought | 0—0.0% | −0.1—−0.5% | 0—0.0% | 0—0.0% | −2.0—−4.5% | 0—0.0% | −0.1—−0.2% | −0.4—−78.4% | 0—0.0% | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | 0—0.0% | −0.9—−3.9% | 0—0.0% | — | — | |
| Cash from investing activities | −0.2—−1.0% | −0.3−141%−1.5% | 0.7—2.9% | −0.7—−1.9% | −2.6—−5.7% | −1.6—−3.7% | −2.1—−9.0% | −0.7−456%−149% | 0.2r0.2—4.3% | −0.1—−6.3% | |
| Shares issued | 0−100%0.0% | 0.1−98.0%0.3% | 2.5—10.3% | 0—0.0% | 0−100%0.0% | 17−11.8%40.0% | 19+74.0%80.4% | 11+1217%2380% | 0.8−58.2%18.5% | 2.0—97.7% | |
| Dividends paid | — | — | — | — | −2.6—−5.7% | −0.4—−0.9% | 0—0.0% | — | — | — | |
| Cash from financing activities | 1.4+11.4%7.5% | 1.3—6.7% | −1.3—−5.5% | −4.0−114%−11.4% | 28+26.2%63.5% | 22+24.8%53.4% | 18+74.7%75.8% | 10+329%2234% | 2.4r2.4−5.0%53.4% | 2.5—124% | |
| Change in cash | — | — | — | — | 12+14.3%26.0% | 10r10+2388%24.2% | 0.4−89.8%1.7% | 4.0+1499%871% | 0.2—5.6% | −0.5—−25.2% | |
| Report | 10-Q | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q3 FY2026to Jun 30, 2026 | Q2 FY2026to Mar 31, 2026 | Q1 FY2026to Dec 31, 2025 | Q4 FY2025to Sep 30, 2025 | Q3 FY2025to Jun 30, 2025 | Q2 FY2025to Mar 31, 2025 | Q1 FY2025to Dec 31, 2024 | Q4 FY2024to Sep 30, 2024 | Q3 FY2024to Jun 30, 2024 | Q2 FY2024to Mar 31, 2024 | Q1 FY2024to Dec 31, 2023 | Q4 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 21+10.0%100% | 5.6+20.6%100% | 5.6+18.8%100% | 5.0−1.9%100% | 4.7*+3.6%100% | 4.6−11.0%100% | 4.7+8.5%100% | 5.1−4.9%100% | 4.6*−20.2%100% | 5.2—100% | 4.4—100% | 5.4—100% | 5.7*—100% | |
| Cost of revenue | 8.9+20.0%42.3% | 2.5+41.7%45.3% | 2.4+33.1%42.3% | 2.0+17.7%40.2% | 1.9*−7.6%41.2% | 1.8+0.3%38.5% | 1.8−0.3%37.7% | 1.7−5.8%33.5% | 2.1*−2.7%46.1% | 1.8—34.2% | 1.8—41.0% | 1.8—33.8% | 2.2*—37.9% | |
| Gross profit | 12+3.7%57.7% | 3.0+7.3%54.7% | 3.3+10.1%57.7% | 3.0−11.7%59.8% | 2.8*+13.2%58.8% | 2.8−16.8%61.5% | 3.0+14.7%62.3% | 3.4−4.4%66.5% | 2.5*−30.9%53.9% | 3.4—65.8% | 2.6—59.0% | 3.6—66.2% | 3.5*—62.1% | |
| Operating income | −2.9—−13.9% | −1.1—−20.4% | −0.8—−14.2% | −0.3—−5.7% | −0.7*—−14.5% | −0.9—−19.6% | −0.5—−10.2% | −0.1—−1.7% | −0.3*—−6.9% | −0.4—−7.4% | −1.6—−35.4% | −1.1—−19.8% | −15*—−266% | |
| Net interest income | 0.0−50.6%0.1% | 0.0−65.2%0.1% | 0.0−63.3%0.0% | 0.0−72.3%0.1% | 0.0*+185%0.1% | 0.0—0.2% | 0.0—0.2% | 0.0—0.2% | 0.0*−97.1%0.0% | −0.0—−0.2% | −0.0—−0.4% | −0.0—−0.0% | 0.1*—1.2% | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | — | −0.1*—−1.0% | |
| Income before tax | −2.9—−13.8% | −1.1—−20.3% | −0.8—−14.1% | −0.3−1976%−5.6% | −0.7*—−14.4% | −0.9−295%−19.4% | −0.5—−10.1% | 0.0—0.3% | −0.2*—−3.4% | 0.5—8.9% | −3.0—−68.8% | −1.0—−18.5% | −16*—−278% | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0*—0.0% | |
| Net income attributable to shareholders | −2.9—−13.8% | −1.1—−20.3% | −0.8—−14.1% | −0.3−1976%−5.6% | −0.7*—−14.4% | −0.9−295%−19.4% | −0.5—−10.1% | 0.0—0.3% | −0.2—−3.4% | 0.5—8.9% | −3.0—−68.8% | −1.0—−18.5% | −16—−278% | |
| Earnings per share, basic | — | -0.11—— | -0.08—— | -0.04—— | — | -0.21—— | -1.90—— | -1.73r-0.22—— | — | -8.93r-0.15—— | -10.84r-1.35—— | -0.67—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | — | -0.15—— | -1.35—— | — | — | |
| Shares, weighted average (basic) | 11+83.6%— | 11+83.6%— | 10+1242%— | 9.0+1482%— | — | 5.8+1188%— | 0.8+110%— | 0.6r4.6−80.8%— | — | 0.4r3.6—— | 0.4r3.0—— | 3.0—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | — | — | — | 3.0—— | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.1—16.1% | 2.1+99.9%16.1% | 2.6+49.5%21.5% | 3.4+72.0%28.8% | 2.3−7.8%21.7% | 1.1−55.8%10.7% | 1.8−16.2%16.1% | 2.0+30.9%17.1% | 2.5+36.4%23.2% | 2.4—17.3% | 2.1—14.5% | 1.5—10.0% | 1.8—11.1% | |
| Receivables | 0.9—7.1% | 0.9+24.2%7.1% | 0.8+18.2%6.7% | 0.7+18.0%6.3% | 0.8+26.5%7.5% | 0.7−18.5%7.5% | 0.7−20.0%6.3% | 0.6+9.4%5.5% | 0.6−48.9%5.9% | 0.9—6.6% | 0.9—6.0% | 0.6—3.8% | 1.2r0.6—7.5% | |
| Inventory | 3.5—26.4% | 3.5+9.0%26.4% | 3.7+26.6%29.8% | 3.1+27.2%26.7% | 2.9+16.7%28.3% | 3.2−1.5%32.1% | 2.9−16.4%26.4% | 2.5−33.9%21.4% | 2.5−40.4%23.9% | 3.2—23.3% | 3.5—23.7% | 3.7—24.8% | 4.2r4.2—26.2% | |
| Other current assets | 0.3—2.6% | 0.3−7.8%2.6% | 0.5+8.5%4.2% | 0.5−21.4%4.3% | 0.3r0.3−31.9%2.7% | 0.4−44.5%3.7% | 0.5−48.6%4.4% | 0.6−35.4%5.5% | 0.4−45.8%3.8% | 0.7—4.8% | 0.9—6.4% | 1.0—6.5% | 0.8—4.6% | |
| Current assets | 7.7—58.5% | 7.7+37.5%58.5% | 8.4+35.4%68.4% | 8.2+28.4%69.3% | 6.6+2.5%62.9% | 5.6−23.2%56.6% | 6.2−16.4%56.6% | 6.4−13.6%55.1% | 6.4−20.8%60.4% | 7.3—52.7% | 7.4—50.9% | 7.4—48.8% | 8.1—49.8% | |
| Property, plant and equipment | 0.3—2.5% | 0.3−3.0%2.5% | 0.4−16.6%2.9% | 0.4−24.2%3.3% | 0.3−38.9%2.7% | 0.3−37.6%3.5% | 0.4−35.2%4.0% | 0.5−35.2%4.4% | 0.5−36.6%4.3% | 0.6—4.0% | 0.7—4.6% | 0.8—5.2% | 0.7—4.4% | |
| Right-of-use (leased) assets | 2.2—16.6% | 2.2+150%16.6% | 0.4−65.3%3.0% | 0.5−55.9%4.5% | 0.7+720%6.8% | 0.9−64.6%8.8% | 1.0−62.3%9.5% | 1.2−60.5%10.5% | 0.1−97.4%0.8% | 2.5—17.8% | 2.8—19.0% | 3.1—20.3% | 3.4—20.7% | |
| Goodwill | 0.2—1.4% | 0.2—1.4% | 0.2—1.6% | — | 0—0.0% | — | — | — | — | — | — | — | 0—0.0% | |
| Other intangible assets | 2.0—15.1% | 2.0−14.6%15.1% | 2.2−12.5%17.9% | 2.1r1.9−21.3%18.0% | 2.1−26.5%20.4% | 2.3−14.2%23.4% | 2.5−12.8%22.9% | 2.7−11.4%23.4% | 2.9−10.2%27.3% | 2.7—19.5% | 2.9—19.7% | 3.0—20.2% | 3.2—19.9% | |
| Total assets | 13—100% | 13+32.8%100% | 12+12.0%100% | 12+2.1%100% | 10−1.5%100% | 9.9−28.5%100% | 11−24.8%100% | 12−23.5%100% | 11−34.7%100% | 14—100% | 15—100% | 15—100% | 16—100% | |
| Accounts payable | 1.5—11.4% | 1.5+22.6%11.4% | 1.4+8.2%11.4% | 0.9−24.1%7.5% | 1.2−23.8%11.3% | 1.2−4.4%12.3% | 1.3−0.3%11.8% | 1.2−25.9%10.1% | 1.5−19.2%14.6% | 1.3—9.2% | 1.3—8.9% | 1.6—10.4% | 1.9—11.8% | |
| Current liabilities | 3.1—23.4% | 3.1−14.1%23.4% | 3.0−69.9%24.2% | 2.8−69.7%23.5% | 3.2−62.9%30.7% | 3.6−54.4%36.2% | 9.9+42.3%90.3% | 9.2+53.6%79.4% | 8.6+84.5%81.4% | 7.9—56.8% | 6.9—47.7% | 6.0—39.6% | 4.7—28.8% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0.0—0.0% | |
| Lease liabilities (non-current) | 1.9—14.1% | 1.9+821%14.1% | — | — | 0—0.0% | 0.2−87.3%2.0% | 0.4−78.1%3.7% | 0.6−71.4%5.1% | 0−100%0.0% | 1.6—11.4% | 1.8—12.5% | 2.1—13.7% | 2.4—14.8% | |
| Non-current liabilities | 1.9—14.1% | 1.9+821%14.1% | — | — | 0—0.0% | 0.2−93.2%2.0% | 0.4−91.2%3.7% | 0.6−71.6%5.1% | 0−100%0.0% | 3.0—21.4% | 4.5—31.1% | 2.1—13.8% | 2.5—15.4% | |
| Total liabilities | 4.9—37.5% | 4.9+30.4%37.5% | 3.0−71.1%24.2% | 2.8−71.6%23.5% | 3.2−62.9%30.7% | 3.8−65.0%38.2% | 10−10.4%93.9% | 9.8+21.1%84.6% | 8.6+20.3%81.4% | 11—78.1% | 11—78.8% | 8.1—53.4% | 7.2—44.2% | |
| Retained earnings | −182—−1383% | −182—−1383% | −181—−1474% | −180—−1526% | −179—−1722% | −179—−1810% | −185—−1687% | −183—−1586% | −182—−1721% | −181—−1307% | −180—−1240% | −176—−1168% | −174—−1077% | |
| Shareholders' equity | 8.2—62.5% | 8.2+34.4%62.5% | 9.3+1295%75.8% | 9.0+406%76.5% | 7.2+268%69.3% | 6.1+102%61.8% | 0.7−78.4%6.1% | 1.8−74.7%15.4% | 2.0−78.3%18.6% | 3.0—21.9% | 3.1—21.2% | 7.0—46.6% | 9.0—55.8% | |
| Total liabilities and equity | 13—100% | 13+32.8%100% | 12+12.0%100% | 12+2.1%100% | 10−1.5%100% | 9.9−28.5%100% | 11−24.8%100% | 12−23.5%100% | 11−34.7%100% | 14—100% | 15—100% | 15—100% | 16—100% | |
| Shares outstanding | 11—— | 11+24.8%— | 10+1240%— | 10+81.7%— | 8.9+1711%— | 8.9+137%— | 0.8−74.3%— | 5.5+87.2%— | 0.5r3.9−83.4%— | 3.8—— | 3.0—— | 3.0—— | 3.0—— | |
| Cash-flow statement | ||||||||||||||
| Cash from operating activities | −2.2—−10.6% | −0.4*—−8.0% | −0.7*—−12.8% | −0.8—−16.2% | −0.2*−244%−5.1% | −0.7*−343%−15.3% | −0.2*—−4.0% | −0.3—−6.2% | 0.2*—3.7% | 0.3*—5.6% | −0.7*—−16.1% | −0.1—−2.0% | −0.3*—−4.6% | |
| Capital expenditure | −0.2—−0.9% | −0.0*—−0.3% | −0.0*—−0.1% | −0.2—−3.3% | −0.0*—−0.1% | −0.0*—−0.0% | −0.0*—−0.3% | −0.2—−3.2% | −0.0*—−0.2% | 0*—0.0% | — | −0.2—−3.4% | −0.1*—−2.1% | |
| Cash from investing activities | −0.1—−0.6% | −0.0*—−0.3% | 0.1*—0.9% | −0.2—−3.3% | −0.0*—−0.1% | −0.0*—−0.0% | −0.0*−436%−0.3% | −0.2—−3.2% | −0.1*—−2.4% | 0*—0.0% | 0.0*—0.1% | −0.2—−3.4% | −0.1*—−2.1% | |
| Shares issued | — | — | — | — | 0*−100%0.0% | 0*—0.0% | — | — | 0.0*−100.0%0.0% | 0*—0.0% | — | — | 0.0*—0.1% | |
| Dividends paid | — | — | — | — | — | — | −1.0—−21.1% | −1.0—−19.7% | — | — | −1.0—−22.9% | −1.0—−18.6% | — | |
| Cash from financing activities | 3.4+341164200%16.3% | −0.1*—−1.1% | −0.1*—−1.4% | 2.1—41.9% | 1.4*+144523500%30.6% | 0*—0.0% | 0*−100%0.0% | 0—0.0% | 0.0*—0.0% | 0*—0.0% | 1.3*—29.7% | −0.0—−0.0% | −0.7*—−11.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at cbdMD, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Ronan Kennedy | $300 K | $300 K | $207 K | — |
| 2024Ronan Kennedy | $275 K | $275 K | $181 K | — |
| 2023Kevin MacDermott | $385 K | $385 K | $191 K | — |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at cbdMD, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 6 · New debt 3 · Unregistered share sale 4 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 1
| Filed | What happened | Filing |
|---|---|---|
| Acquisition or sale completedNew debtUnregistered share sale | 8-K | |
| Material agreementBylaws or fiscal year changed | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K | |
| Delisting notice | 8-K/A | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
How cbdMD, Inc. compares in Pharmaceutical
- Market cap$4 M · higher than 3% of 393
- Revenue$19 M · higher than 8% of 324
- Net margin-13.8% · higher than 17% of 313
- Revenue growth-1.5% · higher than 23% of 107
- Price / sales0.2× · lower than 98% of 219
- Price / book0.6× · lower than 94% of 207
- FCF yield-37.3% · higher than 10% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| cbdMD, Inc.🇺🇸 | $4 M | — | -13.8% | -1.5% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Employees:
- As of September 30, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at cbdMD, Inc.? Verify and update this profile — free
Show cbdMD, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.